템피스트 테라퓨틱스TPST 주가

♻️ 재탕[8-K] 중대 사건 — 8-K

[PRE 14A] PRE 14A — PRE 14A

♻️ 재탕[8-K] 중대 사건 — 8-K

♻️ 재탕[8-K] 중대 사건 — 8-K

Tempest Therapeutics Q1 Adj. EPS $(0.50) Misses $(0.28) Estimate

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.28) by 78.57 percent. This is a 84.18 percent increase over losses of $(3.16) per share

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma Announced Cincinnati Children’s Applied Gene and Cell...

[10-Q] 분기 실적 — 10-Q

[8-K] 중대 사건 — 8-K

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

100% complete response rate among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 dual-targeting CD19/BCMA CAR-T across two ongoing Phase 1 trials Favorable safety profile with...

[8-K] 중대 사건 — 8-K